Background: Fabry disease (FD) is caused by a deficiency in the activity of the lysosomal
enzyme, α-galactosidase A (α-Gal A), which leads to globotriaosylceramide (Gb3) …

Background. Fabry disease is an X-linked disorder of glycosphingolipid catabolism that is
the result of an intracellular deficiency in the lysosomal enzyme α-galactosidase A (α-Gal A) …

Background Fabry disease (FD) is an X-linked lysosomal storage disorder resulting from the
α-galactosidase A gene mutations. Enzyme-replacement-therapy (ERT) products for FD …

Background Fabry disease (FD) is a genetic disorder resulting from deficiency of the
lysosomal enzyme α-galactosidase A (α-Gal A), which leads to globotriaosylceramide (GL-3) …

Introduction: Agalsidase alfa and agalsidase beta, recombinant enzyme preparations for
treatment of Fabry disease (FD), have different approved dosing schedules: 0.2 mg/kg and …

Aims Fabry disease (FD) is an X-linked lysosomal storage disorder caused by a deficiency
of the lysosomal enzyme α-galactosidase A (GLA/AGAL), resulting in the lysosomal …

Fabry's disease (FD) is an X‐linked lysosomal storage disorder caused by the deficient
activity of the lysosomal enzyme α‐galactosidase A (α‐Gal A) leading to intracellular …

Fabry disease is a progressive and life-threatening glycolipid storage disorder affecting both
males and females. The primary driver of the disease is the accumulation of glycolipids …

Introduction Enzyme replacement therapy (ERT) with alpha-Galactosidase A (aGal A) may
cause antibody (AB) formation against aGal A in males with Fabry disease (FD). Anti …

BACKGROUND: Fabry disease (FD) is a genetic disorder resulting from deficiency of the
lysosomal enzyme α-galactosidase A (α-Gal A) which leads to globotriaosylceramide (GL-3) …